Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2013.
IntegraGen licenses key biomarker rights from four French institutions
IntegraGen SA (molecular diagnostics for cancer and autism) has been granted rights by four French institutions to the cancer biomarker hsa-miR-31-3p, which the company will use in developing a...
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
The French drugmaker is expanding its neurology activities with the $470m deal.
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.
